Bristol-Myers Squibb, Gilead to Sell Atripla in Canada
October 2, 2006
Expanding on their US joint venture launched in December 2004, drug makers Bristol-Myers Squibb Co. and Gilead Sciences have agreed to market their once-daily HIV treatment Atripla in Canada, pending approval by Health Canada. The companies will jointly file paperwork with Canadian regulators, and they will contribute funding and staff for the additional sales. Atripla -- which combines fixed doses of BMS' Sustiva and Gilead's Viread and Emtriva -- received US Food and Drug Administration approval in July.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.